DENVER, CO – February 1, 2019 – Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that David Steinman has joined as the company’s Vice President of Regulatory Affairs.
David Steinman holds over two decades of experience, including serving as Assistant United States Attorney where he served 5 years handling narcotics-related matters. Following his time with the States Attorney’s Office, he worked for Nestle USA, Sun Microsystems and RE/MAX LLC before becoming General Counsel for Concord Energy.
“As Phoenix Life expands its international operations, we are proud to add David Steinman to our leadership team,” said Phoenix Life Sciences International CEO Martin Tindall. ‘As we move forward with our mission to re-introduce plant-based pharmaceuticals to mainstream healthcare, Mr. Steinman’s role will be to further enhance the transparency and speed with which we navigate the evolving regulatory climates of countries around the world.”
“As global legalization of medical marijuana continues to spread, I stand behind Phoenix Life in providing patients in need with natural pharmaceutical alternatives to traditional treatments,” said David Steinman. “My background in controlled substances, combined with my time serving large corporations, has given me the experience needed to serve Phoenix Life’s unique nuances as medical marijuana moves toward legalization and social acceptance.”
To learn more about Phoenix Life Sciences International, please visit phoenixlife.co.
About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.
Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International Limited are not available on U.S.
Phoenix Life Sciences International Limited does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). The Company does not grow, sell, or distribute cannabis-based products in the United States and is solely involved with the legal distribution of pharmaceutical products that contain active ingredients derived from the cannabis plant within international markets.
Phone: 1.888.717.5655 or international +1.720.699.7222